Clinical Trials
Herald Therapeutics’ clinical trial program is designed to evaluate the safety and efficacy of lung-delivered ThyrOxy in treating patients with acute cardiopulmonary diseases.
Our initial clinical trial was a Phase 1/2A study in ARDS patients to confirm the safety and tolerability of ThyrOxy delivered directly into the lungs as a solution (NCT 04115514).
The Phase 1 study was completed with zero treatment-related Adverse Events (AEs) or Severe Adverse Events (SAEs) and the Phase 2A portion is ongoing. Herald Therapeutics is preparing for a Phase 1/2A clinical trial evaluating the safety of nebulized ThyrOxy in patients with Acute Heart Failure.
No ThyrOxy-related Adverse Events
Meet Bob, our first patient.
DISCLAIMER: HERALD THERAPEUTICS DRUG PRODUCTS ARE INVESTIGATIONAL DRUG CANDIDATES AND HAVE NOT BEEN APPROVED FOR MARKETING BY THE FDA NOR ANY OTHER REGULATORY AGENCIES.